Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Chronic Plaque Psoriasis
Interventions: ARQ-151 0.3% cream, ARQ-151 vehicle cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 31
States / cities: Scottsdale, Arizona • Beverly Hills, California • Encino, California + 26 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions: Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab; Drug
Lead sponsor: Jeffrey Curtis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more

Conditions: Psoriasis
Interventions: Oral supplement containing 200mg Magnolia officinalis bark extract, Placebo; Dietary Supplement
Lead sponsor: Sirt3 LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 5 more

Conditions: Rheumatoid Arthritis, Plaque Psoriasis
Interventions: Etanercept via Autoinjector A, Etanercept via Autoinjector B; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 28
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more

Conditions: Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Hot Springs, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 11 more

Conditions: Psoriasis Vulgaris
Interventions: LEO 90100, Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis
Interventions: tgAAC94 gene therapy vector, tgAAC94 placebo; Genetic
Lead sponsor: Targeted Genetics Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 22
States / cities: Glendale, Arizona • Tuscon, Arizona • Palm Desert, California + 18 more

Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Contact Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Psoriasis
Interventions: Metaderm; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Arthritis, Psoriatic
Interventions: Tofacitinib, Methotrexate, Placebo Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more

Conditions: Psoriasis
Interventions: DSXS Topical product; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year and older
Enrollment: 2,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Plaque Psoriasis
Interventions: Topical TA-102 A, Topical TA-102 B, Topical TA-102 C, Topical TA-102 D, Topical TA-102 E; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Psoriasis, Plaque-type Psoriasis
Interventions: secukinumab, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more

Conditions: Psoriasis
Interventions: 210mg Brodalumab, 140mg Brodalumab, Ustekinumab, Placebo; Biological
Lead sponsor: MedDerm Associates; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Psoriasis Vulgaris
Interventions: Tildrakizumab; Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriatic Arthritis (PsA)
Interventions: Deucravacitinib, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Psoriasis
Interventions: IDP-118 Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Doral, Florida • Miami, Florida • Louisville, Kentucky + 4 more

Conditions: Psoriasis
Interventions: BMS-986165, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 75 more

Conditions: Plaque Psoriasis
Interventions: Roflumilast; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Beverly Hills, California • Northridge, California • San Diego, California + 16 more

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: ABT-874; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 2,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 98
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 80 more

Conditions: Plaque Psoriasis
Interventions: M518101, placebo, Dovonex; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Mobile, Alabama • Fresno, California + 28 more

Conditions: Chronic Plaque-type Psoriasis
Interventions: AIN457, AIN457A, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more

Search by objective public record fields.

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

COVID-19 VaccinE Response in Rheumatology Patients

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions

Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Genetic Analysis of Psoriasis and Psoriatic Arthritis

An Open-Label Study to Assess Safety

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Study to Evaluate Broadlumab vs Placebo and Ustekinumab

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

Open Label Continuation Study in Moderate to Severe Psoriasis

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis